Jak1 Inhibition Is Sufficient for Treatment of Granuloma Annulare

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Frank H. Netter School of Medicine, Quinnipiac University, North Haven, Connecticut, USA.
³ Department of Dermatology, University of Wisconsin, Madison, Wisconsin, USA.
⁴ Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁵ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: william.damsky@yale.edu.

Muhammad H Junejo et al. J Invest Dermatol. 2025.

. 2025 May 16:S0022-202X(25)00484-1.

doi: 10.1016/j.jid.2025.04.030. Online ahead of print.

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
² Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Frank H. Netter School of Medicine, Quinnipiac University, North Haven, Connecticut, USA.
³ Department of Dermatology, University of Wisconsin, Madison, Wisconsin, USA.
⁴ Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
⁵ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA; Department of Pathology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: william.damsky@yale.edu.

No abstract available

Keywords: Abrocitinib; Granuloma annulare; Jak inhibitor.

LinkOut - more resources